Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer; Shirish M. Gadgeel; Hossein Borghaei; Vassiliki A. Papadimitrakopoulou; Amita Patnaik; Steven Powell; Ryan D. Gentzler; Renato Martins; James Stevenson; Shadia I. Jalal; Amit Panwalkar; James Chih‐Hsin Yang; Matthew A. Gubens; Lecia V. Sequist; Mark M. Awad; Joseph Fiore; Yang Ge; Harry Raftopoulos; Leena Gandhi

doi:10.1016/s1470-2045(16)30498-3

Keywords

PemetrexedPembrolizumabCarboplatinMedicineInternal medicineOncologyLung cancerChemotherapyCohortResponse Evaluation Criteria in Solid TumorsPopulationClinical endpointPhases of clinical researchCancerRandomized controlled trialImmunotherapyCisplatin

Affiliated Institutions

Related Publications

Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.

Vassiliki A. Papadimitrakopoulou , Amita Patnaik , Hossein Borghaei +10 more

8031 Background: As monotherapy, the anti–PD-1 antibody pembro has shown robust antitumor activity in advanced NSCLC patients (pts). KEYNOTE-021 evaluated the safety, tolerabili...

2015 Journal of Clinical Oncology 34 citations

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas , Igor Puzanov , Reinhard Dummer +33 more

2015 The Lancet Oncology 1528 citations

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle , Marwan Fakih , Juanita Lopez +18 more

Tumour mutational burden (TMB) has been retrospectively correlated with response to immune checkpoint blockade. We prospectively explored the association of high tissue TMB (tTM...

2020 The Lancet Oncology 2300 citations

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

Purpose In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platin...

2019 Journal of Clinical Oncology 1616 citations

Publication Info

Year: 2016
Type: article
Volume: 17
Issue: 11
Pages: 1497-1508
Citations: 1372
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1372

OpenAlex

Cite This

APA Style

                            
                                
                                    Corey J. Langer, 
                                
                                    Shirish M. Gadgeel, 
                                
                                    Hossein Borghaei
                                
                                et al.
                            
                            (2016). 
                            Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. 
                            The Lancet Oncology
                            , 17
                            (11)
                            , 1497-1508.
                            https://doi.org/10.1016/s1470-2045(16)30498-3
                        

Identifiers

DOI: 10.1016/s1470-2045(16)30498-3